Data as of Mar 13
| -0.33 / -0.91%|
China Biologic Products, Inc. is the non-state-owned plasma-based biopharmaceutical company approved by the Chinese government. Through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products and Guiyang Dalin Biologic Technologies, and its equity investment in Xi'an Huitian Blood Products, the firm is a fully integrated provider of plasma-based biopharmaceuticals, with capabilities spanning from plasma collection to and research and development, to product manufacturing and commercialization. The firm's key products, human albumin and immunoglobin, are often used to treat life-threatening conditions, such as low albumin, hemophilia and other blood diseases. The firm has marketed plasma-based products and a pipeline of new products to drive future growth in the large Chinese plasma market. The company was founded on December 20, 1989 and is headquartered in Shandong Province, China.
|David Xiaoying Gao||Executive Chairman, President & CEO|
|Ming Yang||CFO, Treasurer & Vice President-Compliance|
|Yi-Wu Vincent Xie||Chief Technology Officer|
|Ming Yin||Senior Vice President|
|Zhijing CBPO Liu||Vice President|